TPM3 and neoplasm: Tumor biopsies were tested for TRK expression or NTRK fusions for choice of therapy (n = 5147; 69.0%), differential diagnosis (n = 2056; 27.6%) or resistance analysis after therapy progression (n = 250; 3.4%) (Figure 1C).